Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel in connection with the combination of itm8 and its current portfolio company AddPro
Mandate

Vinge advises Axcel in connection with the combination of itm8 and its current portfolio company AddPro

May 30, 2022 M&A

Axcel, in partnership with Chr. Augustinus Fabrikker, has agreed to acquire the Danish digital transformation partner, itm8, to create a northern European group within end-to-end IT services through a combination with Axcel-owned AddPro.

Over the years, itm8 and AddPro have individually built strong brands and the aim is to jointly expand the offering of IT-services in the northern European area. Vinge assisted Axcel as lead legal advisor in regard to the divestment of AddPro and Swedish law aspects of the combination with itm8.

The transaction is subject to customary regulatory approvals and is expected to close in Q3 2022.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Viktor Lennartsson and Nina Fathjalali (M&A), and Viktoria Owetz Leyva, Sara Dahlros Sköld, Christoffer Widström, Julia Hagelberg and Klara Lundquist (VDR).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026